

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Susanna M. RYBAK et al.
Title: IMMUNOCONJUGATES OF TOXINS, DIRECTED AGAINST MALIGNANT CELLS
Prior Appl. No.: 09/622,613
Prior Appl. Filing Date: August 17, 2000
Examiner: To be assigned
Art Unit: To be assigned

CONTINUING PATENT APPLICATION TRANSMITTAL LETTER

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a divisional application of the above-identified co-pending prior application in which no patenting, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this continuing application. The entire disclosure of the above-identified prior application is considered as being part of the disclosure of the accompanying continuing application and is hereby incorporated by reference therein.

Enclosed are:

- [X] Specification, Claims, Abstract, and Sequence Listing (85 pages); and
- [X] Statement Regarding Submission of Sequence Listing.

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$710.00	\$710.00
Total Claims:	8	- 20	= 0	x \$18.00	= \$0.00
Independents:	2	- 3	= 0	x \$80.00	= \$0.00
If any Multiple Dependent Claim(s) present:				+ \$270.00	= \$0.00
Surcharge under 37 CFR 1.16(e) for late filing of Executed Declaration				+ \$130.00	= \$130.00
				SUBTOTAL:	= \$840.00
[] Small Entity Fees Apply (subtract ½ of above):					= \$0.00
				TOTAL FILING FEE:	= \$840.00

- [X] The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date

Sept. 25, 2001

By

Stephen B Maebius

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 018733/1059

In re patent application of

Susanne M. RYBAK et al.

Group Art Unit: Unknown

Serial No. Unknown

Examiner: Unknown

Filed:

For: IMMUNOCONJUGATES OF TOXINS DIRECTED
AGAINST MALIGNANT CELLS

STATEMENT REGARDING SUBMISSION OF SEQUENCE LISTING

The computer readable form of the Sequence Listing for this application is to be identical with that filed in Application Number 09/622,613, filed August 17, 2000. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer readable form ("CRF") filed in that application as the computer readable form for the instant application. It is understood that the United States Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The Sequence Listing in the present specification contains the same sequence information as found in the CRF of the present application.

Respectfully submitted,

Sept. 25, 2001
Date

Stephen M. Maebius
Stephen M. Maebius
Registration No. 35,264

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569

09961400-092501
T05260-004T9660